Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial involved 800 people with advanced (metastatic) pancreatic cancer. Participants were divided into three groups: one group received a placebo (an inactive substance) plus the chemotherapy drug gemcitabine (322 people), a second group received a medicine called AMG 479 at a lower dose (12 mg/kg) plus gemcitabine (318 people), and a third group received AMG 479 at a higher dose (20 mg/kg) plus gemcitabine (160 people). The trial was measuring overall survival — that is, how long participants lived from the time they joined the study. The reported data shows that the median overall survival — meaning the point at which half of the participants in each group had passed away and half were still alive — was very similar across all three groups. The lower-dose AMG 479 group had a median survival of 7.0 months, the higher-dose AMG 479 group had 7.1 months, and the placebo group had 7.2 months. No secondary outcome measure data was included in the results submitted to ClinicalTrials.gov, so those figures cannot be reported here. It is also worth noting that a large proportion of participants did not complete the study in each group — this is not unusual in trials involving people with advanced cancer, but the reasons were not detailed in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Pancreatic Cancer Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with pancreatic cancer (specifically adenocarcinoma) that has spread to other parts of the body and has not yet been treated.
- Your blood counts, kidneys, and liver are working well enough to meet the trial's health requirements.
- You are generally able to carry out normal daily activities with little or no limitation (confirm with trial site).
Who may not be able to join:
- You have already received chemotherapy or radiation therapy for your pancreatic cancer.
- Your cancer has spread to the brain or spinal cord area.
- You currently have an external drain for bile (a tube placed outside the body to drain bile).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Determine if the Treatment of AMG 479 at 12 mg/kg and/or 20 mg/kg in Combination With Gemcitabine Improves Overall Survival as Compared With Placebo in Combination With Gemcitabine in Subjects With Metastatic Adenocarcinoma of the Pancreas
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.